PeptideStack
5.2kquestions
20kanswers
220users

semaglutide

Page 12 of 20 · 470 questions tagged semaglutide.

470 questions · sorted by votes · page 12 of 20

17 votes 5 answers7k views
Does the SURMOUNT-5 population resemble anyone asking about a GLP-1 receptor agonist here?

Stated plainly: SURMOUNT-5 · a GLP-1 receptor agonist. I have read the primary source rather than the summary, which has left me with more questions. I understand the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by mass_shift_18 9.7k · 7 months ago
17 votes3 answers5.5k views
Does SOUL show oral semaglutide is cardiovascularly equivalent to the injectable?

SOUL tested oral semaglutide 14 mg daily in people with type 2 diabetes and either atherosclerotic cardiovascular disease or chronic kidney disease, and reported a…

oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
asked by dead_volume 56k · 6 months ago
16 votes5 answers24k views
What does the mechanism of semaglutide predict that STEP 8 did not test?

Concretely: semaglutide · STEP 8. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the question is an…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by swirl_dont_shake 10k · 16 months ago
16 votes 5 answers22k views
Has anyone independently verified a GL Biochem semaglutide batch COA?

The specifics, since they change the answer: GL Biochem · semaglutide. Somebody stated this to me confidently and I would like to check it before repeating it. I…

vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by plunger_stop 13k · 13 months ago
16 votes 5 answers21k views
Is a 29G needle the right choice for drawing semaglutide at 3.33 mg/mL?

For reference: a 29G needle · semaglutide · 3.33 mg/mL. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for…

needle-gauge
needle-gauge

Gauge and length selection, the trade-off between draw time and tissue trauma, coring risk with larger-bore needles, and why a fixed-needle…

91 questions
injection-technique
injection-technique

Technique questions: angle, pinch versus flat, aspiration, injection speed, air bubbles, and the handling steps that determine whether you deliver…

96 questions
dead-space
dead-space

The volume trapped in the syringe hub and needle after the plunger bottoms out. It is small in absolute terms and large as a fraction of a small…

117 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by sinead_gaffney 28k · 18 months ago
16 votes 5 answers19k views
Is 25 °C an acceptable storage condition for lyophilised semaglutide?

For reference: 25 °C · semaglutide. Somebody stated this to me confidently and I would like to check it before repeating it. I would accept a well-reasoned negative…

storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by Dr_Marek_Zielinski 27k · 17 months ago
16 votes 2 answers7.4k views
Does the ESSENCE population resemble anyone asking about semaglutide here?

What I am working with: ESSENCE · semaglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by mala_venkatesh 22k · 18 months ago
16 votes0 answers7.2k views
What fraction of loss on semaglutide is lean mass according to ESSENCE?

The particulars: semaglutide · ESSENCE. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including the…

lean-mass
lean-mass

Lean body mass as measured rather than assumed: what DEXA, BIA and air-displacement plethysmography each actually estimate, the body-composition…

127 questions
muscle-loss
muscle-loss

Loss of contractile tissue during energy deficit: what fraction of total loss is lean mass, why the commonly quoted figures are measurement…

39 questions
dexa
dexa

Dual-energy X-ray absorptiometry: what it measures, its precision limits, why hydration state and scan positioning move the numbers, and how to…

39 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by mira_sundqvist 7.1k · 11 months ago
16 votes0 answers4.1k views
Why did my LDL-C move after eight weeks on semaglutide?

Setup, so nobody has to ask: LDL-C · eight weeks · semaglutide. I noticed this today and I have not touched anything since, in case the state is diagnostic. I have…

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
lipids
lipids

Lipid response on treatment: triglycerides, LDL-C, non-HDL-C, ApoB and Lp(a), which of them move with weight loss, and why a fasting panel drawn…

139 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by tadhg_o_riordan 7.7k · 5 months ago
15 votes 5 answers39k views
Is STEP 5 a fair comparison of a GLP-1 receptor agonist against its comparator arm?

Setup, so nobody has to ask: STEP 5 · a GLP-1 receptor agonist. This is asserted often enough that I assumed it was established, and then I went looking for the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by nynke_dekker 9.4k · 2.2 years ago
15 votes 5 answers30k views
What should be in place before a first semaglutide vial arrives from Zhuhai?

Setup, so nobody has to ask: semaglutide · Zhuhai. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I…

harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
research-use-only
research-use-only

What "for research use only" means as a legal and practical designation: not approved for human use, no pharmacopoeial release testing, no…

95 questions
sterility
sterility

Sterility as a test result rather than an adjective. Covers what a sterility test actually measures, why "sterile filtered" on a document is close…

142 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by harriet_lonsdale 35k · 20 months ago
15 votes 5 answers23k views
Does the SURMOUNT-4 population resemble anyone asking about tirzepatide here?

The case in front of me: SURMOUNT-4 · tirzepatide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by ahmed_zerouali 15k · 2.2 years ago
15 votes0 answers21k views
Is SURPASS-3 a fair comparison of tirzepatide against its comparator arm?

Stated plainly: SURPASS-3 · tirzepatide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by mala_venkatesh 22k · 2.2 years ago
15 votes 5 answers14k views
How does a GLP-1 receptor agonist behave on a C8 column compared to semaglutide?

Details up front: a GLP-1 receptor agonist · a C8 column · semaglutide. I have used one of these for a while and I am considering switching, which requires a reason.…

hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
reference-standard
reference-standard

Certified reference materials and in-house standards: traceability, the certificate of the standard itself, system suitability, and why every…

185 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by s_kalniete 57k · 10 months ago
15 votes 5 answers12k views
What fraction of loss on semaglutide is lean mass according to FLOW?

Stated plainly: semaglutide · FLOW. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…

lean-mass
lean-mass

Lean body mass as measured rather than assumed: what DEXA, BIA and air-displacement plethysmography each actually estimate, the body-composition…

127 questions
muscle-loss
muscle-loss

Loss of contractile tissue during energy deficit: what fraction of total loss is lean mass, why the commonly quoted figures are measurement…

39 questions
dexa
dexa

Dual-energy X-ray absorptiometry: what it measures, its precision limits, why hydration state and scan positioning move the numbers, and how to…

39 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by teodora_ilic 17k · 7 months ago
15 votes5 answers11k views
Why do two papers on STEP 5 report different headline figures?

The clinician who ordered the panel was not concerned; I would still like to understand it. I keep seeing this stated as a fact with no explanation attached, and…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by Dr_Aoife_Brennan 20k · 9 months ago
15 votes 5 answers11k views
What does TRIUMPH-1 actually establish about a GLP-1 receptor agonist?

Stated plainly: TRIUMPH-1 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
asked by ilaria_bertone 33k · 4 months ago
15 votes 5 answers9.7k views
Why do two papers on ESSENCE report different headline figures?

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I keep seeing this stated as a fact with no explanation attached,…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by dead_volume 56k · 3 months ago
15 votes0 answers6.7k views
Does the STEP 3 population resemble anyone asking about semaglutide here?

The case in front of me: STEP 3 · semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by p_mkhize 58k · 2.3 years ago
15 votes0 answers6k views
Is there any published stability data for semaglutide at 30 °C?

Conditions: semaglutide · 30 °C. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and monographs without…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by greta_holzmann 23k · 6 months ago
15 votes 5 answers4.4k views
Would you accept 95.2% on semaglutide from SGN without a content assay?

The particulars: 95.2% · semaglutide · SGN. I am at the decision point and I would rather think it through than improvise. I would rather spend money on measurement…

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by pk_curve 30k · 5 months ago
14 votes 5 answers16k views
How much of the gross mass of a 15 mg semaglutide vial is actually peptide?

The particulars: 15 mg · semaglutide. I would like the arithmetic checked rather than the conclusion asserted. I have deliberately not used an online calculator…

content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
water-content
water-content

Residual moisture in a lyophilised solid, measured by Karl Fischer titration or loss on drying. It drives both the mass balance on a content assay…

51 questions
acetate-content
acetate-content

Counter-ion content, most often acetate or trifluoroacetate, and why it matters: the counter-ion and residual water are part of the gross mass you…

88 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by sample_id 17k · 2.1 years ago
14 votes0 answers16k views
Is an 18G drawing needle the right choice for drawing semaglutide at 20 mg/mL?

The specifics, since they change the answer: an 18G drawing needle · semaglutide · 20 mg/mL. I am trying to choose between two options that are usually discussed as…

needle-gauge
needle-gauge

Gauge and length selection, the trade-off between draw time and tissue trauma, coring risk with larger-bore needles, and why a fixed-needle…

91 questions
injection-technique
injection-technique

Technique questions: angle, pinch versus flat, aspiration, injection speed, air bubbles, and the handling steps that determine whether you deliver…

96 questions
dead-space
dead-space

The volume trapped in the syringe hub and needle after the plunger bottoms out. It is small in absolute terms and large as a fraction of a small…

117 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by tare_weight 60k · 2.1 years ago
14 votes 3 answers14k views
How comparable are cagrilintide and semaglutide on the evidence available?

Setup, so nobody has to ask: cagrilintide · semaglutide. I have used one of these for a while and I am considering switching, which requires a reason. What I care…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
asked by u100_marks 52k · 9 months ago